Current Report Filing (8-k)
March 31 2021 - 11:32AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event
reported): March 31, 2021
BRAIN
SCIENTIFIC INC.
(Exact Name of Registrant as Specified
in Charter)
Nevada
|
|
333-209325
|
|
81-0876714
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
125 Wilbur Place, Suite 170
Bohemia, NY 11716
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number,
including area code: (917) 388-1578
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Not applicable
|
Not applicable
|
Not applicable
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging Growth Company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 7.01
|
Regulation FD Disclosure.
|
On March 31, 2021, Brain Scientific Inc.
issued a press release announcing that it received its first purchase order for its NeuroCap, a pre-gelled, disposable EEG headset,
from the Department of Veterans Affairs - VA Medical Centers for one of its hospitals.
The press release furnished as Exhibit
99.1 to this Current Report on Form 8-K is incorporated herein by reference. The information in this Item 7.01 and in Exhibit 99.1
of Item 9.01 is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will
not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1 of Item 9.01.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: March 30, 2021
|
BRAIN SCIENTIFIC INC.
|
|
|
|
By:
|
/s/ Boris Goldstein
|
|
Name:
|
Boris Goldstein
|
|
Title:
|
Chairman of the Board, Secretary
and Executive Vice President
|
|
|
|
Brain Scientific (CE) (USOTC:BRSF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Brain Scientific (CE) (USOTC:BRSF)
Historical Stock Chart
From Jul 2023 to Jul 2024